RESUMEN
OBJECTIVE: To perform a comparative analysis of the efficacy of the original drug meloxicam (movalis) and its generic (amelotex) in the treatment of patients with lower back pain. MATERIALS AND METHODS: The analysis of treatment results of 112 (61 men and 51 women) employees of JSC «Admiralteyskie Verfi¼, aged 18 to 60 years, was carried out. All these patients were treated in the period from 2015 to 2017 at the Medical Center of JSC «Admiralteyskie Verfi¼ due to dorsalgia of lumbosacral localization (ICD-10, item M54). The average age of the patients was 42,6±10,4 (from 22 to 59 years). Age range of patients was 20-35 years (n=34); 36-50 years (n=49); >50 years (n=29). RESULTS: Compared to amelotex, movalis was more effective for the duration of pain intensity reduction (5±1,4 days (min 3, max 9) in the movalis group and 7,37±1,68 days (min 3, max 10) in the amelotex group) as well as for the total duration of temporary disability (labor losses 6,43±1,4 days (min 4, max 10) and 8,61±1,59 days (min 5, max 12), respectively). In addition, patients receiving movalis showed a more significant improvement in the Clinical Global Impression (CGI) score in all age groups compared with patients in the amelotex group. CONCLUSION: The lack of therapeutic equivalence between movalis and amelotex determines the relevance of the drug choice for complex therapy of these patients, which will improve the prognosis of the disease and the quality of life of the patient.